| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1092689071 |
| P356 | DOI | 10.1007/S40265-017-0830-1 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s40265-017-0830-1 |
| P932 | PMC publication ID | 5733787 |
| P698 | PubMed publication ID | 29143192 |
| P50 | author | Lisa Hensley | Q4795006 |
| Peter B. Jahrling | Q29452352 | ||
| Jason Kindrachuk | Q47036869 | ||
| P2093 | author name string | Reed F Johnson | |
| Jason Kindrachuk | |||
| Matthew B Frieman | |||
| Julie Dyall | |||
| Gene G Olinger | |||
| Robin Gross | |||
| P2860 | cites work | State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans | Q21128649 |
| Infection with MERS-CoV causes lethal pneumonia in the common marmoset | Q21131359 | ||
| Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus | Q21131361 | ||
| A systematic screen of FDA-approved drugs for inhibitors of biological threat agents | Q21559667 | ||
| A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA | Q24289279 | ||
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe | Q24289281 | ||
| Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report | Q24289287 | ||
| A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report | Q24289295 | ||
| Ebola virus uses clathrin-mediated endocytosis as an entry pathway | Q24301618 | ||
| A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry | Q24306622 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. | Q24568225 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings | Q38864793 | ||
| Middle East Respiratory Syndrome (MERS). | Q38874573 | ||
| Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of Global Health Burden | Q38888319 | ||
| Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus | Q38895828 | ||
| The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins. | Q39010414 | ||
| Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle | Q39252753 | ||
| Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidates | Q39332343 | ||
| The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients | Q39361532 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection | Q39378324 | ||
| Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis | Q39388390 | ||
| Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK. | Q39424035 | ||
| 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). | Q39472319 | ||
| Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells | Q39521948 | ||
| Involvement of cyclophilin B in the replication of Japanese encephalitis virus | Q39600135 | ||
| Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection | Q39677274 | ||
| Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication | Q39695623 | ||
| Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection | Q34261999 | ||
| Antiviral drugs specific for coronaviruses in preclinical development | Q34332580 | ||
| HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. | Q34333815 | ||
| Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission | Q34347979 | ||
| Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity | Q34392620 | ||
| Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein | Q34408840 | ||
| Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp | Q34426585 | ||
| Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen | Q34442119 | ||
| Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis | Q34452682 | ||
| Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus | Q34455805 | ||
| Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases | Q34457869 | ||
| Protease inhibitors targeting coronavirus and filovirus entry | Q34461982 | ||
| Coronaviruses: an overview of their replication and pathogenesis. | Q34464697 | ||
| Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates | Q34473079 | ||
| Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial | Q34488529 | ||
| Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease | Q34507610 | ||
| Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys | Q34516555 | ||
| A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection | Q34542427 | ||
| Myosin-actin interaction plays an important role in human immunodeficiency virus type 1 release from host cells | Q34562034 | ||
| Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications | Q34583259 | ||
| Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes | Q34636137 | ||
| Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels | Q34641515 | ||
| MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment | Q34650943 | ||
| Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms | Q34725136 | ||
| Strategies in the design of antiviral drugs | Q34741530 | ||
| Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication | Q34786769 | ||
| A Computational Approach for Predicting Role of Human MicroRNAs in MERS-CoV Genome. | Q34813357 | ||
| Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus | Q35008480 | ||
| Middle East respiratory syndrome coronavirus in bats, Saudi Arabia | Q24596439 | ||
| Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection | Q24646403 | ||
| Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes | Q24676817 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells | Q26248879 | ||
| From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design | Q26992345 | ||
| The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis | Q27001157 | ||
| Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance | Q27488307 | ||
| Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein | Q27488982 | ||
| Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors | Q27648952 | ||
| Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor | Q27689029 | ||
| Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease | Q27696384 | ||
| Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 | Q27702268 | ||
| Animal models of Middle East respiratory syndrome coronavirus infection | Q28086778 | ||
| HIV-1 protease: mechanism and drug discovery | Q28202791 | ||
| Bats are natural reservoirs of SARS-like coronaviruses | Q28274751 | ||
| Investigational drug available directly from CDC for the treatment of infections with free-living amebae | Q28297051 | ||
| Effects of protease inhibitors on replication of various myxoviruses | Q28318487 | ||
| ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease | Q28369297 | ||
| A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults | Q28475036 | ||
| Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine | Q28476738 | ||
| Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis | Q28477369 | ||
| Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection | Q28486226 | ||
| Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library | Q28534763 | ||
| Hydrocarbon-stapled peptides: principles, practice, and progress | Q28542025 | ||
| Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial | Q28551448 | ||
| Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection | Q28588877 | ||
| Identification of a candidate therapeutic autophagy-inducing peptide | Q28593490 | ||
| The druggable genome | Q29547361 | ||
| Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
| Protein kinases--the major drug targets of the twenty-first century? | Q29615339 | ||
| Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling | Q29617453 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections | Q35019893 | ||
| Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs | Q35050840 | ||
| Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response | Q35076795 | ||
| Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus | Q35085075 | ||
| Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells | Q35123537 | ||
| Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein | Q35159147 | ||
| Loperamide therapy for voluminous diarrhea in Ebola virus disease | Q35197376 | ||
| Treatment of hepatitis C: a systematic review | Q35223637 | ||
| A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs | Q35468247 | ||
| Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease | Q35487986 | ||
| Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. | Q35536588 | ||
| Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits | Q35641228 | ||
| Lack of protection against ebola virus from chloroquine in mice and hamsters | Q35673457 | ||
| Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease | Q35683735 | ||
| Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists | Q35706815 | ||
| Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection | Q35718193 | ||
| Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity | Q35739055 | ||
| Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study | Q35763702 | ||
| Review of bats and SARS | Q35793577 | ||
| Into the eye of the cytokine storm | Q35804633 | ||
| A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge | Q35855727 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity | Q35867238 | ||
| Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro | Q35878870 | ||
| A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease | Q35908575 | ||
| Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity | Q35911482 | ||
| Cyclosporin A inhibits the replication of diverse coronaviruses | Q35960586 | ||
| Small molecules targeting severe acute respiratory syndrome human coronavirus | Q35970698 | ||
| Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | Q35989939 | ||
| Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry | Q36086649 | ||
| Development of antiviral therapy for severe acute respiratory syndrome. | Q36119173 | ||
| Antiviral RNAi therapy: emerging approaches for hitting a moving target | Q36264167 | ||
| SARS: clinical presentation, transmission, pathogenesis and treatment options | Q36367782 | ||
| Nidovirus transcription: how to make sense...? | Q36475903 | ||
| Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 | ||
| Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection | Q39964308 | ||
| Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. | Q40017118 | ||
| Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. | Q40042137 | ||
| Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. | Q40092859 | ||
| Pharmacology of Antidiarrheal Drugs | Q40135927 | ||
| Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses | Q40137530 | ||
| The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. | Q40250047 | ||
| Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection | Q40287482 | ||
| Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins | Q40376973 | ||
| A mouse model for MERS coronavirus-induced acute respiratory distress syndrome | Q40433408 | ||
| Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha | Q40439150 | ||
| Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). | Q40505474 | ||
| Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus | Q40534160 | ||
| Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study | Q40543264 | ||
| Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. | Q40544493 | ||
| Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China | Q40554400 | ||
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Q40568140 | ||
| Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference | Q40585048 | ||
| Inhibition of arenavirus multiplication in vitro by phenotiazines | Q40666672 | ||
| Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo | Q40787125 | ||
| Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset | Q41096904 | ||
| Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses | Q41600623 | ||
| Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. | Q41718118 | ||
| Acidotropic amines inhibit proteolytic processing of flavivirus prM protein | Q41745865 | ||
| Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species | Q41771247 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. | Q41927429 | ||
| Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. | Q41932765 | ||
| Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice | Q41943954 | ||
| Interferon-beta 1a and SARS coronavirus replication | Q42042092 | ||
| Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome | Q42214884 | ||
| Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. | Q42229748 | ||
| Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study | Q42244203 | ||
| An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus | Q42256274 | ||
| Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. | Q42264009 | ||
| Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides | Q42719737 | ||
| Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors | Q42858751 | ||
| Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha | Q42988927 | ||
| First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. | Q42993891 | ||
| Effect of cantharidin, cephalotaxine and homoharringtonine on "in vitro" models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication | Q43037386 | ||
| Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus | Q43042207 | ||
| Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study | Q43042527 | ||
| The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. | Q43046668 | ||
| Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine | Q43048066 | ||
| Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model | Q43194438 | ||
| Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. | Q43523397 | ||
| Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype | Q44480907 | ||
| Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase | Q44653963 | ||
| Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation | Q44749529 | ||
| 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 | Q36626864 | ||
| Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus | Q36691163 | ||
| Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi | Q36726714 | ||
| Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection | Q36816625 | ||
| The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies | Q36827306 | ||
| Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus | Q36872701 | ||
| Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein | Q36972346 | ||
| A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes | Q37135539 | ||
| Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease | Q37211511 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques | Q37236553 | ||
| Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors | Q37252823 | ||
| Pneumonia from human coronavirus in a macaque model | Q37273712 | ||
| Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. | Q37336487 | ||
| Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway | Q37511523 | ||
| Replicative Capacity of MERS Coronavirus in Livestock Cell Lines | Q37513472 | ||
| Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets | Q37547173 | ||
| Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics | Q37549382 | ||
| Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays | Q37593209 | ||
| Divergent roles of autophagy in virus infection | Q37679218 | ||
| Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. | Q37723794 | ||
| Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. | Q37835939 | ||
| Astemizole: an old anti-histamine as a new promising anti-cancer drug | Q37858580 | ||
| Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology | Q37862783 | ||
| Loperamide | Q37894244 | ||
| Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections | Q37913363 | ||
| A review of palivizumab and emerging therapies for respiratory syncytial virus | Q37914882 | ||
| Therapeutics against influenza | Q37975932 | ||
| Chikungunya virus: an update on antiviral development and challenges | Q38107673 | ||
| Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection | Q38122005 | ||
| Chloroquine: modes of action of an undervalued drug | Q38124637 | ||
| Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity | Q38208100 | ||
| T cell-mediated immune response to respiratory coronaviruses | Q38213199 | ||
| FDA-approved small-molecule kinase inhibitors. | Q38480289 | ||
| A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection. | Q38730484 | ||
| Toremifene interacts with and destabilizes the Ebola virus glycoprotein | Q38760720 | ||
| Rapid generation of a mouse model for Middle East respiratory syndrome | Q30217177 | ||
| Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. | Q30230264 | ||
| In vitro inhibition of human influenza A virus replication by chloroquine | Q30230591 | ||
| Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion | Q30276258 | ||
| A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity | Q30279239 | ||
| Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. | Q30354466 | ||
| Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. | Q30362113 | ||
| Antiviral combinations for severe influenza. | Q30366719 | ||
| Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial | Q30402402 | ||
| Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection | Q30419612 | ||
| Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin | Q30429521 | ||
| Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. | Q30432156 | ||
| Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein | Q30439990 | ||
| Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection | Q30448355 | ||
| Advances in antivirals for non-influenza respiratory virus infections | Q30457132 | ||
| Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies | Q30805028 | ||
| Cyclophilins: a new family of proteins involved in intracellular folding. | Q30888628 | ||
| Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease | Q33217732 | ||
| A clinical drug library screen identifies astemizole as an antimalarial agent | Q33248659 | ||
| Small molecule regulators of autophagy identified by an image-based high-throughput screen | Q33306309 | ||
| Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay | Q33317900 | ||
| Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study | Q33409373 | ||
| Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection | Q33413007 | ||
| Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. | Q33415278 | ||
| A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection | Q33514831 | ||
| A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection | Q33573571 | ||
| Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 | ||
| Coronaviruses post-SARS: update on replication and pathogenesis | Q33694361 | ||
| Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro | Q33788800 | ||
| Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein | Q33788831 | ||
| Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. | Q33797817 | ||
| Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques | Q33887877 | ||
| Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication | Q33918489 | ||
| Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 | ||
| On chikungunya acute infection and chloroquine treatment | Q34012738 | ||
| Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. | Q34040052 | ||
| A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. | Q34051627 | ||
| Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture | Q34058365 | ||
| Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic | Q34069846 | ||
| Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays | Q34113650 | ||
| Mefloquine in the treatment of progressive multifocal leukoencephalopathy | Q34121699 | ||
| Phenothiazine: the seven lives of pharmacology's first lead structure | Q34159168 | ||
| Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. | Q34167398 | ||
| Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. | Q38797421 | ||
| Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights | Q38826176 | ||
| Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. | Q45013422 | ||
| Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor | Q45113065 | ||
| Inhibition of SARS-CoV replication by siRNA. | Q45206542 | ||
| Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. | Q45745621 | ||
| Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives. | Q45922806 | ||
| The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. | Q46409785 | ||
| Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids | Q46467408 | ||
| Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients | Q46500144 | ||
| Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus | Q46505019 | ||
| Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers | Q46588982 | ||
| Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease | Q46711512 | ||
| Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques | Q48015946 | ||
| Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. | Q50572228 | ||
| Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. | Q50576529 | ||
| Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. | Q50787284 | ||
| Middle East respiratory syndrome. | Q51011540 | ||
| Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases--United States and worldwide, December 2003. | Q51639374 | ||
| Inhibition of SARS-associated coronavirus infection and replication by RNA interference. | Q51641137 | ||
| The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. | Q54413526 | ||
| Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses | Q55966493 | ||
| Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers | Q57177960 | ||
| Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication | Q63561195 | ||
| Inhibition of SV40 DNA replication in vitro by chlorpromazine | Q70473131 | ||
| Structural determinants responsible for the biological activity of (-)-emetine, (-)-cryptopleurine, and (-)-tylocrebrine: structure-activity relationship among related compounds | Q71310307 | ||
| Risks of non-sedating antihistamines | Q73321169 | ||
| Treatment of SARS with human interferons | Q73738906 | ||
| [Anisomycin in intestinal amebiasis; study of 30 clinical cases] | Q74427893 | ||
| Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors | Q80849382 | ||
| Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy | Q83263799 | ||
| Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials | Q84666257 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | severe acute respiratory syndrome | Q103177 |
| Middle East | Q7204 | ||
| Middle East respiratory syndrome | Q16654806 | ||
| RNA virus infectious disease | Q18967413 | ||
| Middle East respiratory syndrome coronavirus | Q4902157 | ||
| coronavirus disease | Q18975243 | ||
| antiviral agent | Q40207875 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-11-15 | |
| 2017-12-01 | |||
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies |
| Q98944137 | A protein interaction map identifies existing drugs targeting SARS-CoV-2 |
| Q94563683 | Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus |
| Q94672299 | Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season |
| Q97551132 | Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations |
| Q59360930 | Drug Repurposing for Viral Infectious Diseases: How Far Are We? |
| Q93154238 | Déjà vu: Stimulating open drug discovery for SARS-CoV-2 |
| Q98831074 | Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis |
| Q92119967 | Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of A Pandemic |
| Q94685789 | Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial |
| Q104289159 | Identification of antiviral antihistamines for COVID-19 repurposing |
| Q97519947 | Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches |
| Q96352766 | Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities |
| Q98215904 | Management of epigenomic networks entailed in coronavirus infections and COVID-19 |
| Q87461749 | Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China |
| Q84315456 | Membrane binding proteins of coronaviruses |
| Q57094095 | Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice |
| Q90482543 | Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
| Q95290134 | Novel coronavirus 2019 (COVID-19): Emergence and implications for emergency care |
| Q66679577 | Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections |
| Q98565106 | Psychoactive compounds as multifactorial protection factors against COVID-19 |
| Q92740650 | Repurposing approved drugs on the pathway to novel therapies |
| Q97533909 | Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer |
| Q98288123 | The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus P |
| Q90751270 | The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients |
| Q95297445 | The current understanding and potential therapeutic options to combat COVID-19 |
| Q90060949 | Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures |
| Q94489350 | [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic] |
Search more.